|
Exemestane Compared With Tamoxifen in Treating Postmenopausal Women With Breast Cancer Clinical Trials Information presented on Clinical Trials Search is not intended to be a substitute for qualified health advice, trips or treatment by using a genuine doctor. We aren't doctors. Always consult your mD on Exemestane Compared With Tamoxifen in Treating Postmenopausal Women With Breast Cancer conditions. Clinical Trials Search.org is a site committed to listing clinical research studies in human subjects. Exemestane Compared With Tamoxifen in Treating Postmenopausal Women With Breast Cancer Clinical research trials and Exemestane Compared With Tamoxifen in Treating Postmenopausal Women With Breast Cancer health trials take place in a lot of of cities across the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally measure the potency of new drugs. The aim of the studies / projects is to answer specific human medical questions. Clinical trials are a popular manner for physicians, government agencies, and private sector corporations to discover remedies for all kinds of circumstances, like Exemestane Compared With Tamoxifen in Treating Postmenopausal Women With Breast Cancer. Exemestane Compared With Tamoxifen in Treating Postmenopausal Women With Breast Cancer Clinical Trials and other clinical trials allow for volunteers to have health treatment alternatives before they are available to the general public. Many times the test subjects obtain treatment for without cost, and occasionally they are paid for their time. Sometimes there is a cost for a Exemestane Compared With Tamoxifen in Treating Postmenopausal Women With Breast Cancer clinical trial. Subjects oftentimes recieve the most effective healthcare possible for their Exemestane Compared With Tamoxifen in Treating Postmenopausal Women With Breast Cancer condition. Hazards are a reality, however, and could include additional or frequent doctor visits, healthcare dangers (perhaps life-threatening), and/or the treatment being ineffective. Trials are federally governed with exacting guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "E" Clinical Trials Conditions > Exemestane Compared With Tamoxifen in Treating Postmenopausal Women With Breast Cancer  Exemestane Compared With Tamoxifen in Treating Postmenopausal Women With Breast Cancer
Exemestane Compared With Tamoxifen in Treating Postmenopausal Women With Breast Cancer
For Condition: stage 1 breast cancer,stage 2 breast cancer
Status: Recruiting
Sponsor(s): Cancer Research Campaign Clinical Trials Centre ,
Synopsis: RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using exemestane may fight breast cancer by reducing the production of estrogen. It is not yet known if exemestane is more effective than tamoxifen in preventing the recurrence of breast cancer. PURPOSE: Randomizedphase III trial to compare the effectiveness of exemestane with that of tamoxifen in treating postmenopausal women who have undergone surgery to remove early-stage breast cancer.
Details: OBJECTIVES: - Compare the efficacy and tolerability of adjuvant exemestane versus adjuvant tamoxifen in postmenopausal women with early breast cancer. - Compare the relapse-free survival and overall survival of patients treated with these drugs. - Compare the incidence of contralateral breast cancer in patients treated with these drugs. - Compare the safety and long-term tolerability of these drugs in these patients. - Compare the quality of life of patients treated with these drugs. OUTLINE: This is a randomized, open-label, multicenter study. Patients are stratified according to estrogen receptor (ER)/progesterone receptor (PgR) status (ER positive vs ER negative/PgR positive vs ER positive/PgR unknown), prior chemotherapy (none vs taxane-based vs anthracycline-based vs other), and nodal status (negative vs 1-3 nodes positive vs 4 or more nodes positive). Patients are randomized to 1 of 2 treatment arms. - Arm I: Patients receive oral tamoxifen once daily - Arm II: Patients receive oral exemestane once daily. Treatment in both arms continues for a minimum of 5 years in the absence of disease progression or unacceptable toxicity. Quality of life is assessed at baseline and at months 3 and 12 during study. Patients are followed at least annually. PROJECTED ACCRUAL: Approximately 4,400 patients (2,200 per treatment arm) will be accrued for this study.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: /
Genders: Both
Protocol Entry Criteria: DISEASE CHARACTERISTICS: - Histologically or cytologically confirmed early adenocarcinoma of the breast - Completely excised by surgery with curative intent (R0) - Any N OR - Any primary tumor greater than 3 cm OR - Any primary tumor grade III and greater than 1 cm - M0 - No positive supraclavicular nodes - Hormone receptor status: - Estrogen and/or progesterone receptor positive PATIENT CHARACTERISTICS: Age: - Any age - See Menopausal status Sex: - Female Menopausal status: - Postmenopausal - Any age with bilateral oophorectomy or amenorrhea for at least 5 years OR - Age 50 or over: - Natural amenorrhea for at least 1 year OR - Chemotherapy-induced amenorrhea for at least 2 years OR - Radiation-induced amenorrhea (at least 3 months since prior radiotherapy) OR - Under age 50: - If amenorrheic for less than 5 years (any cause) or prior hysterectomy without bilateral surgical oophorectomy, follicle-stimulating hormone must be assayed to confirm postmenopausal status Performance status: - ECOG 0-2 Life expectancy: - Not specified Hematopoietic: - Platelet count greater than 100,000/mm3 - WBC greater than 3,000/mm3 Hepatic: - SGOT or SGPT less than 2.5 times upper limit of normal (ULN) Renal: - Creatinine less than 1.5 times ULN Cardiovascular: - No uncontrolled cardiac disease - No unstable angina - No congestive heart failure or arrhythmia requiring medical therapy - No myocardial infarction within the past 3 months Other: - No severe osteoporosis - No other malignancies within the past 5 years except adequately treated carcinoma in situ of the cervix or basal cell skin cancer - No other serious concurrent disease that would preclude study - No psychiatric disorders that would preclude study PRIOR CONCURRENT THERAPY: Biologic therapy: - Not specified Chemotherapy: - No prior neoadjuvant chemotherapy - No more than 10 weeks since completion of prior adjuvant chemotherapy Endocrine therapy: - No prior adjuvant hormonal therapy for breast cancer - No prior neoadjuvant hormonal therapy (prior to surgery) for duration of more than 4 weeks - At least 4 weeks since prior hormone replacement therapy Radiotherapy: - Not specified Surgery: - See Disease Characteristics - No more than 10 weeks since completion of curative surgery Other: - No other concurrent investigational agents or participation in another clinical study (except adjuvant cytotoxic chemotherapy studies) - Concurrent bisphosphonates allowed
Total Enrollment:
Location and Contact Information:
Overall Study Official:
DanielRea, Study Chair, City Hospital - Birmingham
City Hospital - Birmingham *Recruiting*
Birmingham, England, B18 7QH
United Kingdom
Recruiting Daniel Rea 44-121-507-5241
Additional Information:
Study ID Numbers: CDR0000069260; EU-20149,CRC-TU-TEAM
Study Start Date:
Record last reviewed: March 2002
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00032136
Other Stage 1 Breast Cancer Studies:
1. Gene Therapy Plus Chemotherapy in Treating Patients With Breast Cancer
2. Comparison of Complete Axillary Lymph Node Dissection With Axillary Radiation Therapy in Treating Women With Invasive Breast Cancer
3. Exemestane in Treating Postmenopausal Women With Resected Stage I, Stage II, or Stage IIIA Breast Cancer Who Have Completed 5 Years of Tamoxifen
4. Combination Chemotherapy in Treating Women With Breast Cancer Who Have Undergone Surgery
5. Letrozole or Tamoxifen in Treating Postmenopausal Women With Breast Cancer
Related Studies:
Other stage 1 breast cancer Clinical Trials
Other England Clinical Trials
Other Birmingham Clinical Trials
Exemestane Compared With Tamoxifen in Treating Postmenopausal Women With Breast Cancer
|
|
|
|
|
|
|
|
